PUBBLICAZIONI TEAM DIABETE

1. **In humans increase in intrapancreatic adipose tissue predicts beta-cell dedifferentiation score before diabetes onset: A pilot study.** Cinti F, Mezza T, Severi I, Moffa S, Giuseppe GD, Capece U, Ciccarelli G, Soldovieri L, Brunetti M, Morciano C, Gugliandolo S, Senzacqua M, Avolio A, Quero G, Tondolo V, Nista EC, Moroni R, Cinti S, Alfieri S, Gasbarrini A, Pontecorvi A, Giaccari A. Diabetes Res Clin Pract. 2025 Mar; 221:112029. doi: 10.1016/j.diabres.2025.112029. Epub 2025 Feb 10. Diabetes Res Clin Pract. 2025 Mar 17:112097. PMID: 39938572.
2. **Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes**. Cinti F, Leccisotti L, Sorice GP, Capece U, D'Amario D, Lorusso M, Gugliandolo S, Morciano C, Guarneri A, Guzzardi MA, Mezza T, Capotosti A, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, Giaccari A. Cardiovasc Diabetol. 2023 Dec 19;22(1):349. doi: 10.1186/s12933-023-02091-0. PMID: 38115004; PMCID: PMC10731727.
3. **The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?** Cinti F, Laborante R, Cappannoli L, Morciano C, Gugliandolo S, Pontecorvi A, Burzotta F, Donniacuo M, Cappetta D, Patti G, Giaccari A, D'Amario D. Cardiovasc Diabetol. 2025 May 14;24(1):208. doi: 10.1186/s12933-025-02767-9. PMID: 40369599; PMCID: PMC12079913.
4. **Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in Humans.** Di Giuseppe G, Gliozzo G, Ciccarelli G, Carciero L, Brunetti M, Soldovieri L, Quero G, Cinti F, Nista EC, De Lucia SS, Gasbarrini A, Alfieri S, Pontecorvi A, Mari A, Hartmann B, Holst JJ, Giaccari A, Mezza T. J Clin Endocrinol Metab. 2025 May 12:dgaf210. doi: 10.1210/clinem/dgaf210. Epub ahead of print. PMID: 40354158.
5. **SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.** Morciano C, Gugliandolo S, Capece U, Di Giuseppe G, Mezza T, Ciccarelli G, Soldovieri L, Brunetti M, Avolio A, Splendore A, Pontecorvi A, Giaccari A, Cinti F. Cardiovasc Diabetol. 2024 Dec 19;23(1):449. doi: 10.1186/s12933-024-02539-x. PMID: 39702365; PMCID: PMC11660748.
6. **Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features** Capece U, Moffa S, Improta I, Di Giuseppe G, Nista EC, Cefalo CMA, Cinti F, Pontecorvi A, Gasbarrini A, Giaccari A, Mezza T. Nutrients. 2022 Dec 21;15(1):18. doi: 10.3390/nu15010018. PMID: 36615676; PMCID: PMC9824456.
7. **Beta-cell function and glucose metabolism in patients with chronic pancreatitis.** Ciccarelli G, Di Giuseppe G, Soldovieri L, Quero G, Nista EC, Brunetti M, Cinti F, Moffa S, Capece U, Tondolo V, Mari A, Gasbarrini A, Pontecorvi A, Alfieri S, Giaccari A, Mezza T. Eur J Intern Med. 2024 Oct;128:112-118. doi: 10.1016/j.ejim.2024.06.007. Epub 2024 Jun 12. PMID: 38871564.
8. **Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.** Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2. PMID: 30291013.
9. **Publish and perish**. Giaccari A. Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1035-1036.

doi: 10.1016/j.numecd.2017.11.002. PMID: 29198555.
10. **EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)**. Lancet. 2021 Nov 6;398(10312):1713-1725. doi: 10.1016/S0140-6736(21)01122-3. Epub 2021 Sep 7. PMID: 34506743.
11. **GLIMPLES study investigators. Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.** Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A; Diabetes Obes Metab. 2024 Jun;26(6):2390-2400. doi: 10.1111/dom.15554. Epub 2024 Mar 13. PMID: 38477183.
12. **DARWIN-Renal Study Investigators. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.** Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. PMID: 38328413; PMCID: PMC10847023.
13. **Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis.** Sajiir H, Wong KY, Müller A, Keshvari S, Burr L, Aiello E, Mezza T, Giaccari A, Sebastiani G, Dotta F, Ramm GA, Macdonald GA, McGuckin MA, Prins JB, Hasnain SZ. Nat Commun. 2024 May 29;15(1):4527. doi: 10.1038/s41467-024-48320-2. PMID: 38811550; PMCID: PMC11137127.
14. **Welcome aboard.** Giaccari A. Nutr Metab Cardiovasc Dis. 2015 Jan;25(1):1-2. doi: 10.1016/j.numecd.2014.12.003. PMID: 25599990.
15. **SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.** Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A, Monami M; Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2745-2755. doi: 10.1016/j.numecd.2021.06.002. Epub 2021 Jul 5. PMID: 34364771.
16. **Expanding the Use of SGLT2i in Diabetes Beyond Type 2.** Giaccari A. Diabetes Care. 2024 Jan 1;47(1):50-51. doi: 10.2337/dci23-0065. PMID: 38117995.
17. **Endocrine and Metabolic Insights from Pancreatic Surgery.** Mezza T, Cefalo CMA, Cinti F, Quero G, Pontecorvi A, Alfieri S, Holst JJ, Giaccari A. Trends Endocrinol Metab. 2020 Oct;31(10):760-772. doi: 10.1016/j.tem.2020.07.003. Epub 2020 Aug 20. PMID: 32830029.
18. **Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia**. Olmastroni E, Gazzotti M, Averna M, Arca M, Tarugi P, Calandra S, Bertolini S, Catapano AL, Casula M; LIPIGEN Study Group *. J Am Heart Assoc. 2023 May 16;12(10):e029223. doi: 10.1161/JAHA.122.029223. Epub 2023 May 15. PMID: 37183858; PMCID: PMC10227296
19. **European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study.** Lancet Diabetes Endocrinol. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4. PMID: 39374602.

20. **The interplay of extracellular vesicles in the pathogenesis of metabolic impairment and type 2 diabetes**. Carciero L, Di Giuseppe G, Di Piazza E, Parand E, Soldovieri L, Ciccarelli G, Brunetti M, Gasbarrini A, Nista EC, Pani G, Pontecorvi A, Giaccari A, Mezza T. Diabetes Res Clin Pract. 2024 Oct;216:111837. doi: 10.1016/j.diabres.2024.111837. Epub 2024 Aug 21. PMID: 39173679.
21. **First-phase insulin secretion: can its evaluation direct therapeutic approaches?** Di Giuseppe G, Ciccarelli G, Soldovieri L, Capece U, Cefalo CMA, Moffa S, Nista EC, Brunetti M, Cinti F, Gasbarrini A, Pontecorvi A, Giaccari A, Mezza T. Trends Endocrinol Metab. 2023 Apr;34(4):216-230. doi: 10.1016/j.tem.2023.02.001. Epub 2023 Feb 27. PMID: 36858875.
22. **Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.** Leccisotti L, Cinti F, Sorice GP, D'Amario D, Lorusso M, Guzzardi MA, Mezza T, Gugliandolo S, Cocchi C, Capece U, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, Giaccari A. Cardiovasc Diabetol. 2022 Sep 3;21(1):173. doi: 10.1186/s12933-022-01607-4. PMID: 36057768; PMCID: PMC9440459.
23. **Reduced incretin effect precedes diabetes development following duodenopancreatectomy in individuals without diabetes.** Di Giuseppe G, Soldovieri L, Ciccarelli G, Ferraro PM, Quero G, Cinti F, Capece U, Moffa S, Nista EC, Gasbarrini A, Mari A, Alfieri S, Tondolo V, Pontecorvi A, Holst JJ, Giaccari A, Mezza T. J Clin Invest. 2024 Mar 12;134(8):e175133. doi: 10.1172/JCI175133. PMID: 38470487; PMCID: PMC11014652.
24. **The Interplay between Immune System and Microbiota in Diabetes.** Mediators Inflamm. Moffa S, Mezza T, Cefalo CMA, Cinti F, Impronta F, Sorice GP, Santoro A, Di Giuseppe G, Pontecorvi A, Giaccari A. 2019 Dec 30;2019:9367404. doi: 10.1155/2019/9367404. PMID: 32082078; PMCID: PMC7012204.
25. **Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives**. Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A. Cardiovasc Diabetol. 2019 Feb 28;18(1):20. doi: 10.1186/s12933-019-0828-y. PMID: 30819210; PMCID: PMC6393994.
26. **LIPIGEN Group and the LIPIGEN Paediatric Group**. **Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study. Atherosclerosis.** Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, Pederiva C. 2023 Nov;385:117231. doi: 10.1016/j.atherosclerosis.2023.117231. Epub 2023 Aug 12. PMID: 37648636.
27. **An update on pancreatic regeneration mechanisms: Searching for paths to a cure for type 2 diabetes.** Soldovieri L, Di Giuseppe G, Ciccarelli G, Quero G, Cinti F, Brunetti M, Nista EC, Gasbarrini A, Alfieri S, Pontecorvi A, Giaccari A, Mezza T. Mol Metab. 2023 Aug;74:101754. doi: 10.1016/j.molmet.2023.101754. Epub 2023 Jun 13. PMID: 37321370; PMCID: PMC10331309.
28. **Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?** Giaccari A, Solini A, Frontoni S, Del Prato S. Diabetes Care. 2021 Mar;44(3):647-654. doi: 10.2337/dc20-1964. PMID: 33608326; PMCID: PMC7896249.
29. **Open questions on basal insulin therapy in T2D: a Delphi consensus.** Delphi Board; Buzzetti R, Candido R, Esposito K, Giaccari A, Mannucci E, Nicolucci A, Russo GT. Acta Diabetol. 2024 Oct;61(10):1267-1281. doi: 10.1007/s00592-024-02285-2. Epub 2024 May 20. PMID: 38767675; PMCID: PMC11486792.

30. **Lysophosphatidylinositols Are Upregulated After Human β-Cell Loss and Potentiate Insulin Release.** Jiménez-Sánchez C, Sinturel F, Mezza T, Loizides-Mangold U, Montoya JP, Li L, Di Giuseppe G, Quero G, Guessous I, Jornayvaz F, Schrauwen P, Stenvers DJ, Alfieri S, Giaccari A, Berishvili E, Compagnon P, Bosco D, Riezman H, Dibner C, Maechler P.Diabetes. 2024 Jan 1;73(1):93-107. doi: 10.2337/db23-0205. PMID: 37862465.
31. **Lynch Syndrome and Thyroid Nodules: A Single Center Experience. Genes (Basel).** Spinelli I, Moffa S, Fianchi F, Mezza T, Cinti F, Di Giuseppe G, Marmo C, Ianiro G, Ponziani FR, Tortora A, Riccioni ME, Giaccari A, Gasbarrini A. 2024 Jun 30;15(7):859. doi: 10.3390/genes15070859. PMID: 39062638; PMCID: PMC11275478.
32. **Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.** Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, Mezza T, Giaccari A Drug Des Devel Ther. 2017 Oct 3;11:2905-2919. doi: 10.2147/DDDT.S114932. PMID: 29042751; PMCID: PMC5633300.
33. **Sodium-glucose co-transporter inhibitors: Medications that mimic fasting for cardiovascular prevention.** Giaccari A. Diabetes Obes Metab. 2019 Oct;21(10):2211-2218. doi: 10.1111/dom.13814. Epub 2019 Jul 5. PMID: 31209982.
34. **Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis.** Ciccarelli G, Di Giuseppe G, Cinti F, Moffa S, Mezza T, Giaccari A. Diabetes Metab Res Rev. 2023 Oct;39(7):e3668. doi: 10.1002/dmrr.3668. Epub 2023 Jun 12. PMID: 37309298.
35. **Physical Activity and Type 2 Diabetes: In Search of a Personalized Approach to Improving β-Cell Function.** Di Murro E, Di Giuseppe G, Soldovieri L, Moffa S, Improta I, Capece U, Nista EC, Cinti F, Ciccarelli G, Brunetti M, Gasbarrini A, Pontecorvi A, Giaccari A, Mezza T. Nutrients. 2023 Sep 28;15(19):4202. doi: 10.3390/nu15194202. PMID: 37836486; PMCID: PMC10574038.
36. **Italian guidelines for the treatment of type 2 diabetes.** Mannucci E, Candido R, Delle Monache L, Gallo M, Giaccari A, Masini ML, Mazzone A, Medea G, Pintaudi B, Targher G, Trento M, Turchetti G, Lorenzoni V, Monami M for Società Italiana di Diabetologia (SID) and Associazione Medici Diabetologi (AMD); Nutr Metab Cardiovasc Dis. 2022 Apr;32(4):770-814. doi: 10.1016/j.numecd.2022.01.027. Epub 2022 Feb 4. PMID: 35227550.
37. **SGLT2i Increase Endogenous Glucose Production: That's Good News!** Giaccari A. Diabetes Care. 2022 Jun 2;45(6):1301-1302. doi: 10.2337/dci22-0010. PMID: 35653601.
38. **β-Cell Fate in Human Insulin Resistance and Type 2 Diabetes: A Perspective on Islet Plasticity.** Mezza T, Cinti F, Cefalo CMA, Pontecorvi A, Kulkarni RN, Giaccari A. Diabetes. 2019 Jun;68(6):1121-1129. doi: 10.2337/db18-0856. PMID: 31109941; PMCID: PMC6905483.
39. **Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences.** DI Giuseppe G, Ciccarelli G, Cefalo CM, Cinti F, Moffa S, Impronta F, Capece U, Pontecorvi A, Giaccari A, Mezza T. Minerva Endocrinol (Torino). 2021 Sep;46(3):272-292. doi: 10.23736/S2724-6507.21.03405-9. Epub 2021 Jul 5. PMID: 34218657.
40. **Italian guidelines for the treatment of type 2 diabetes.** Mannucci E, Candido R, Monache LD, Gallo M, Giaccari A, Masini ML, Mazzone A, Medea G, Pintaudi B, Targher G, Trento M, Turchetti G, Lorenzoni V, Monami M; for Società Italiana di Diabetologia (SID) and Associazione Medici Diabetologi (AMD). Acta Diabetol. 2022 May;59(5):579-622. doi: 10.1007/s00592-022-01857-4. Epub 2022 Mar 15. PMID: 35288805; PMCID:

PMC8995274.

41. **Exploring nutraceutical approaches linking metabolic syndrome and cognitive impairment.** Sonnino R, Ciccarelli G, Moffa S, Soldovieri L, Di Giuseppe G, Brunetti M, Cinti F, Di Piazza E, Gasbarrini A, Nista EC, Pontecorvi A, Giaccari A, Mezza T. iScience. 2025 Jan 23;28(2):111848. doi: 10.1016/j.isci.2025.111848. PMID: 40008362; PMCID: PMC11850164.
42. **Come superare le barriere all'implementazione delle strategie di prevenzione e cura della malattia cardiovascolare aterosclerotica mediante terapia ipolipemizzante** Arca M, Averna M, Borghi C, Lettino M, Perrone Filardi P, Alberti A, Bilato C, Calabrò P, Carubbi F, Ciccone MM, Cipollone F, Citroni N, De Luca L, Giaccari A, Iannuzzo G, Maloberti A, Marcucci R, Pignatelli Spinazzola P, Pirro M, Pisciotta L, Sarullo F, Sciacqua A, Suppressa P, Varbella F, Werba JP, Zambon A. G Ital Cardiol (Rome). 2023 Oct;24(10):770-780. Italian. doi: 10.1714/4100.40977. PMID: 37767829.
43. **SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.** Giaccari A, Pontremoli R, Perrone Filardi P. Int J Cardiol. 2022 Mar 15;351:66-70. doi: 10.1016/j.ijcard.2021.12.050. Epub 2022 Jan 1. PMID: 34979145.
44. **A single-center prospective analysis of the impact of glucose metabolism on pancreatic fistula onset after pancreaticoduodenectomy for periampullary tumors.** Quero G, Laterza V, Di Giuseppe G, Lucinato C, Massimiani G, Nista EC, Sionne F, Biffoni B, Brunetti M, Rosa F, De Sio D, Ciccarelli G, Fiorillo C, Menghi R, Langellotti L, Soldovieri L, Gasbarrini A, Pontecorvi A, Giaccari A, Alfieri S, Tondolo V, Mezza T. Am J Surg. 2024 Dec;238:115987. doi: 10.1016/j.amjsurg.2024.115987. Epub 2024 Sep 24. PMID: 39342881.
45. **SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.** Mannucci E, Targher G, Nreu B, Pintaudi B, Candido R, Giaccari A, Gallo M, Monami M; Nutr Metab Cardiovasc Dis. 2022 Jun;32(6):1353-1360. doi: 10.1016/j.numecd.2022.03.007. Epub 2022 Mar 15. PMID: 35422359.
46. **Comprehensive sequencing profile and functional analysis of IsomiRs in human pancreatic islets and beta cells.** Diabetologia. 2025 Jun;68(6):1261-1278. doi: 10.1007/s00125-025-06397-4. Epub 2025 Mar 18. PMID: 40102237; PMCID: PMC12069488.
47. **Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.** Fioretto P, Giaccari A, Sesti G. Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. PMID: 26474563; PMCID: PMC4609166.
48. **Human subjects with impaired beta-cell function and glucose tolerance have higher levels of intra-islet intact GLP-1.** Mezza T, Wewer Albrechtsen NJ, Di Giuseppe G, Ferraro PM, Soldovieri L, Ciccarelli G, Brunetti M, Quero G, Alfieri S, Nista EC, Gasbarrini A, Tondolo V, Mari A, Pontecorvi A, Giaccari A, Holst JJ. Metabolism. 2025 Feb;163:156087. doi: 10.1016/j.metabol.2024.156087. Epub 2024 Dec 1. PMID: 39626843.
49. **Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails.** Mannucci E, Giaccari A, Gallo M, Bonifazi A, Belén ÁDP, Masini ML, Trento M, Monami M. Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):330-336. doi: 10.1016/j.numecd.2021.10.005. Epub 2021 Oct 14. PMID: 34893413.
50. **Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs**

glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H. Diabetes Obes Metab. 2018 Mar;20(3):541-548. doi: 10.1111/dom.13105. Epub 2017 Oct 5. PMID: 28862801; PMCID: PMC5836995.

51. **What Is the Best Medicine for Chronic Kidney Disease in Diabetes?** Giaccari A. Diabetes Care. 2022 Dec 1;45(12):2814-2816. doi: 10.2337/dci22-0029. PMID: 36455128.
52. **2023 update on Italian guidelines for the treatment of type 2 diabetes.** Mannucci E, Candido R, Monache LD, Gallo M, Giaccari A, Masini ML, Mazzone A, Medea G, Pintaudi B, Targher G, Trento M, Turchetti G, Lorenzoni V, Monami M; for Società Italiana di Diabetologia (SID) and Associazione Medici Diabetologi (AMD). Acta Diabetol. 2023 Aug;60(8):1119-1151. doi: 10.1007/s00592-023-02107-x. Epub 2023 May 26. PMID: 37233852; PMCID: PMC10290044.
53. **Evaluation of guidelines on diabetes medication.** Giaccari A, Giorda CB, Riccardi G, De Micheli A, Bruno G, Monge L, Frontoni S. Ann Intern Med. 2012 May 15;156(10):752-3; author reply 753. doi: 10.7326/0003-4819-156-10-201205150-00020. PMID: 22586015.
54. **Increased β-Cell Workload Modulates Proinsulin-to-Insulin Ratio in Humans.** Mezza T, Ferraro PM, Sun VA, Moffa S, Cefalo CMA, Quero G, Cinti F, Sorice GP, Pontecorvi A, Folli F, Mari A, Alfieri S, Giaccari A. Diabetes. 2018 Nov;67(11):2389-2396. doi: 10.2337/db18-0279. Epub 2018 Aug 21. PMID: 30131390.
55. **SID-AMD joint Panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.** Monami M, Candido R, Pintaudi B, Targher G, Mannucci E; Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):699-704. doi: 10.1016/j.numecd.2020.11.031. Epub 2020 Dec 10. PMID: 33549430.
56. **Removal of duodenum elicits GLP-1 secretion.** Muscogiuri G, Mezza T, Prioletta A, Sorice GP, Clemente G, Sarno G, Nuzzo G, Pontecorvi A, Holst JJ, Giaccari A. Diabetes Care. 2013 Jun;36(6):1641-6. doi: 10.2337/dc12-0811. Epub 2013 Feb 7. PMID: 23393218; PMCID: PMC3661831.
57. **Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study.** Moffa S, Mezza T, Ferraro PM, Di Giuseppe G, Cefalo CMA, Cinti F, Impronta F, Capece U, Ciccarelli G, Mari A, Pontecorvi A, Giaccari A. Front Endocrinol (Lausanne). 2023 May 31;14:1124116. doi: 10.3389/fendo.2023.1124116. PMID: 37324254; PMCID: PMC10266211.
58. **Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.** Buzzetti R, Bonadonna RC, Giaccari A, Perseghin G, Cucinotta D, Fanelli C, Avogaro A, Aimaretti G, Larosa M, Pacchetti I, Bolli GB. Diabetes Obes Metab. 2022 Feb;24(2):327-331. doi: 10.1111/dom.14560. Epub 2021 Oct 22. PMID: 34595824; PMCID: PMC9297992.
59. **The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach.** Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G. Curr Diabetes Rev. 2011 Sep;7(5):313-24. doi: 10.2174/157339911797415585. PMID: 21838680.
60. **Insulin resistance alters islet morphology in nondiabetic humans.** Mezza T, Muscogiuri G, Sorice GP, Clemente G, Hu J, Pontecorvi A, Holst JJ, Giaccari A, Kulkarni RN. Diabetes. 2014 Mar;63(3):994-1007. doi: 10.2337/db13-1013. Epub 2013 Nov 11. PMID: 24215793; PMCID: PMC3931397.

61. **Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor.** Capece U, Gugliandolo S, Morciano C, Avolio A, Splendore A, Di Giuseppe G, Ciccarelli G, Soldovieri L, Brunetti M, Mezza T, Pontecorvi A, Giaccari A, Cinti F.Nutrients. 2024 Dec 14;16(24):4318. doi: 10.3390/nu16244318. PMID: 39770939; PMCID: PMC11676811.
62. **Circulating 1,5-Anhydroglucitol as a Biomarker of ß-cell Mass Independent of a Diabetes Phenotype in Human Subjects.** Jiménez-Sánchez C, Mezza T, Sinturel F, Li L, Di Giuseppe G, Quero G, Jornayvaz FR, Guessous I, Dibner C, Schrauwen P, Alfieri S, Giaccari A, Maechler P. J Clin Endocrinol Metab. 2022 Sep 28;107(10):2833-2843. doi: 10.1210/clinem/dgac444. PMID: 35867405.
63. **LIPIGEN Group. Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).** Averna M, Cefalù AB, Casula M, Noto D, Arca M, Bertolini S, Calandra S, Catapano AL, Tarugi P; Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001. PMID: 28965615.
64. **Lipid-Lowering-Relevance Study Group. Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes.** Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A; Cardiovasc Diabetol. 2022 Apr 26;21(1):57. doi: 10.1186/s12933-022-01495-8. Erratum in: Cardiovasc Diabetol. 2022 May 13;21(1):73. doi: 10.1186/s12933-022-01515-7. PMID: 35473579; PMCID: PMC9044595.
65. **Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes.** Brusco N, Sebastiani G, Di Giuseppe G, Licata G, Grieco GE, Fignani D, Nigi L, Formichi C, Aiello E, Auddino S, Quero G, Cefalo CMA, Cinti F, Mari A, Ferraro PM, Pontecorvi A, Alfieri S, Giaccari A, Dotta F, Mezza T. Diabetologia. 2023 Feb;66(2):354-366. doi: 10.1007/s00125-022-05814-2. Epub 2022 Oct 25. PMID: 36280617; PMCID: PMC9807540.
66. **Pancreaticoduodenectomy model demonstrates a fundamental role of dysfunctional β cells in predicting diabetes.** Mezza T, Ferraro PM, Di Giuseppe G, Moffa S, Cefalo CM, Cinti F, Impronta F, Capece U, Quero G, Pontecorvi A, Mari A, Alfieri S, Giaccari A. J Clin Invest. 2021 Jun 15;131(12):e146788. doi: 10.1172/JCI146788. PMID: 33905373; PMCID: PMC8203447.
67. **Peroxiredoxin 6, a novel player in the pathogenesis of diabetes.** Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, Federici M, Sconocchia G, Tesauro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, Lauro D. Diabetes. 2014 Oct;63(10):3210-20. doi: 10.2337/db14-0144. Epub 2014 Jun 19. PMID: 24947358.
68. **Lipid-Lowering-Relevance Study Group. Correction to: Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes.** Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A; Cardiovasc Diabetol. 2022 May 13;21(1):73. doi: 10.1186/s12933-022-01515-7. Erratum for: Cardiovasc Diabetol. 2022 Apr 26;21(1):57. doi: 10.1186/s12933-022-01495-8. PMID: 35562766; PMCID: PMC9103295.
69. **A Systematic Comparison of Protocols for Recovery of High-Quality RNA from Human Islets Extracted by Laser Capture Microdissection.** Cefalo CMA, Mezza T, Giaccari A, Kulkarni RN. Biomolecules. 2021 Apr 22;11(5):625. doi: 10.3390/biom11050625. PMID: 33922227; PMCID: PMC8144988.
70. **Advancing Diabetes Research: A Novel Islet Isolation Method from Living Donors.** Di

Piazza E, Todi L, Di Giuseppe G, Soldovieri L, Ciccarelli G, Brunetti M, Quero G, Alfieri S, Tondolo V, Pontecorvi A, Gasbarrini A, Nista EC, Giaccari A, Pani G, Mezza T. Int J Mol Sci. 2024 May 29;25(11):5936. doi: 10.3390/ijms25115936. PMID: 38892122; PMCID: PMC11172646.

71. **SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials.** Mannucci E, Gallo M, Pintaudi B, Targher G, Candido R, Giaccari A, Monami M; Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):511-514. doi: 10.1016/j.numecd.2021.10.010. Epub 2021 Nov 1. PMID: 34893404.
72. **DARWIN-T2D network. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.** Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A; Diabetes Obes Metab. 2018 Jul;20(7):1781-1786. doi: 10.1111/dom.13280. Epub 2018 Mar 30. PMID: 29516612; PMCID: PMC6175069.
73. **β-Cell Glucose Sensitivity Is Linked to Insulin/Glucagon Bihormonal Cells in Nondiabetic Humans**. Mezza T, Sorice GP, Conte C, Sun VA, Cefalo CM, Moffa S, Pontecorvi A, Mari A, Kulkarni RN, Giaccari A. J Clin Endocrinol Metab. 2016 Feb;101(2):470-5. doi: 10.1210/jc.2015-2802. Epub 2015 Dec 9. PMID: 26649619; PMCID: PMC4880124.
74. **Identification and Molecular Characterization of a Novel Large-Scale Variant (Exons 4_18 Loss) in the LDLR Gene as a Cause of Familial Hypercholesterolaemia in an Italian Family.** Concolino P, De Paolis E, Moffa S, Onori ME, Soldovieri L, Ricciardi Tenore C, De Bonis M, Rabacchi C, Santonocito C, Rinelli M, Calandra S, Giaccari A, Urbani A, Minucci A. Genes (Basel). 2023 Jun 16;14(6):1275. doi: 10.3390/genes14061275. PMID: 37372455; PMCID: PMC10298720.
75. **SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.** Mannucci E, Gallo M, Giaccari A, Candido R, Pintaudi B, Targher G, Monami M; Diabetes Obes Metab. 2023 Feb;25(2):444-453. doi: 10.1111/dom.14888. Epub 2022 Oct 24. PMID: 36205446.
76. **Identification of two novel LDLR variants by Next Generation Sequencing. Ann Ist Super Sanita.** Moffa S, Mazzuccato G, De Bonis M, De Paolis E, Onori ME, Pontecorvi A, Urbani A, Giaccari A, Capoluongo E, Minucci A. 2020 Jan-Mar;56(1):122-127. doi: 10.4415/ANN_20_01_17. PMID: 32242544.
77. **Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.** Mezza T, Moffa S, Ferraro PM, Quero G, Capece U, Carfì A, Cefalo CMA, Cinti F, Sorice GP, Impronta F, Mari A, Pontecorvi A, Alfieri S, Holst JJ, Giaccari A. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2685-2694. doi: 10.1210/jc.2018-02804. PMID: 30874733.
78. **Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.** Olmastroni E, Gazzotti M, Arca M, Averna M, Pirillo A, Catapano AL, Casula M; LIPIGEN Study Group†. J Am Heart Assoc. 2022 Apr 5;11(7):e023668. doi: 10.1161/JAHA.121.023668. Epub 2022 Mar 24. PMID: 35322671; PMCID: PMC9075429.

79. **Genetic disruption of SOD1 gene causes glucose intolerance and impairs β-cell function.** Muscogiuri G, Salmon AB, Aguayo-Mazzucato C, Li M, Balas B, Guardado-Mendoza R, Giaccari A, Reddick RL, Reyna SM, Weir G, Defronzo RA, Van Remmen H, Musi N. Diabetes. 2013 Dec;62(12):4201-7. doi: 10.2337/db13-0314. Epub 2013 Sep 5. PMID: 24009256; PMCID: PMC3837066.
80. **Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial.** Cefalo CMA, Conte C, Sorice GP, Moffa S, Sun VA, Cinti F, Salomone E, Muscogiuri G, Brocchi AAG, Pontecorvi A, Mezza T, Giaccari A. EObesity (Silver Spring). 2018 Apr;26(4):651-657. doi: 10.1002/oby.22132. Epub 2018 Mar 4. PMID: 29504254; PMCID: PMC6175391.
81. **Metabolic consequences of the occlusion of the main pancreatic duct with acrylic glue after pancreaticoduodenectomy** Mezza T, Clemente G, Sorice GP, Conte C, De Rose AM, Sun VA, Cefalo CM, Pontecorvi A, Nuzzo G, Giaccari A. Am J Surg. 2015 Oct;210(4):783-9. doi: 10.1016/j.amjsurg.2014.12.052. Epub 2015 Apr 30. PMID: 26004536.
82. **Erythrocyte membrane fluidity: A novel biomarker of residual cardiovascular risk in type 2 diabetes.** Bianchetti G, Cefalo CMA, Ferreri C, Sansone A, Vitale M, Serantoni C, Abeltino A, Mezza T, Ferraro PM, De Spirito M, Riccardi G, Giaccari A, Maulucci G. Eur J Clin Invest. 2024 Mar;54(3):e14121. doi: 10.1111/eci.14121. Epub 2023 Nov 6. PMID: 37929812.
83. **DARWIN-FUP network. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study.** Morieri ML, Raz I, Consoli A, Rigato M, Lapolla A, Broglio F, Bonora E, Avogaro A, Fadini GP; J Endocrinol Invest. 2023 Jul;46(7):1429-1439. doi: 10.1007/s40618-022-02002-2. Epub 2023 Jan 9. PMID: 36624223; PMCID: PMC10261249.
84. **Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.** Sorice GP, Cinti F, Leccisotti L, D'Amario D, Lorusso M, Guzzardi MA, Mezza T, Cocchi C, Capece U, Ferraro PM, Crea F, Giordano A, Iozzo P, Giaccari A. Diabetes Ther. 2021 Jul;12(7):2101-2113. doi: 10.1007/s13300-021-01083-1. Epub 2021 May 26. PMID: 34037951; PMCID: PMC8266960.
85. **Will vitamin D reduce insulin resistance? Still a long way to go.** Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Am J Clin Nutr. 2011 Mar;93(3):672-3; author reply 673-4. doi: 10.3945/ajcn.110.009068. Epub 2011 Jan 5. PMID: 21209228.
86. **HCC development is associated to peripheral insulin resistance in a mouse model of NASH.** De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, Candelaresi C, Giaccari A, Trozzi L, Pierantonelli I, Mingarelli E, Marzioni M, Muscogiuri G, Gaggini M, Benedetti A, Gastaldelli A, Guido M, Svegliati-Baroni G. PLoS One. 2014 May 22;9(5):e97136. doi: 10.1371/journal.pone.0097136. PMID: 24853141; PMCID: PMC4031080.
87. **Single-fiber conduction velocity test allows earlier detection of abnormalities in diabetes.** Padua L, Stålberg E, Caliandro P, Muscogiuri G, Pazzaglia C, Sorice GP, Granata G, Salomone E, Pontecorvi A, Giaccari A. Muscle Nerve. 2011 May;43(5):652-6. doi: 10.1002/mus.21935. PMID: 21484824.
88. **Potential cause-effect relationship between insulin autoimmune syndrome and alpha lipoic acid: Two case reports.** Moffa S, Improta I, Rocchetti S, Mezza T, Giaccari A. Nutrition. 2019 Jan;57:1-4. doi: 10.1016/j.nut.2018.04.010. Epub 2018 May 25. PMID:

30086435.
89. **Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis.** Blasetti Fantauzzi C, Iacobini C, Menini S, Vitale M, Sorice GP, Mezza T, Cinti S, Giaccari A, Pugliese G. Sci Rep. 2020 Nov 18;10(1):20070. doi: 10.1038/s41598-020-76952-z. PMID: 33208796; PMCID: PMC7675972.
90. **A novel low-density lipoprotein receptor variant in a Ukrainian patient: a case report and overview of the disease-causing low-density lipoprotein receptor variants associated to familial hypercholesterolemia.** Moffa S, Onori ME, De Paolis E, Ricciardi Tenore C, Perrucci A, Pontecorvi A, Giaccari A, Urbani A, Minucci A. Mol Biol Rep. 2022 Feb;49(2):1623-1630. doi: 10.1007/s11033-021-07015-3. Epub 2021 Nov 30. PMID: 34846648
91. **Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.** Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, Sawhney S. Diab Vasc Dis Res. 2021 Jan-Feb;18(1):1479164121995928. doi: 10.1177/1479164121995928. PMID: 33611925; PMCID: PMC8481733.
92. **Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.** Giaccari A, Bonadonna RC, Buzzetti R, Perseghin G, Cucinotta D, Fanelli C, Avogaro A, Aimaretti G, Larosa M, Pagano V, Bolli GB. Acta Diabetol. 2021 Jun;58(6):789-796. doi: 10.1007/s00592-021-01675-0. Epub 2021 Feb 14. PMID: 33586058; PMCID: PMC8110495.
93. **Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021-2022.** Capece U, Iacomini C, Mezza T, Cesario A, Masciocchi C, Patarnello S, Giaccari A, Di Giorgi N. Lipids Health Dis. 2024 Jul 24;23(1):224. doi: 10.1186/s12944-024-02221-x. PMID: 39049007; PMCID: PMC11267803.
94. **β-Adrenergic Responsive Induction of Insulin Resistance in Liver of Aging Rats.** Muscogiuri G, Kamat A, Balas B, Giaccari A, Defronzo RA, Musi N, Katz MS. Endocr Res. 2011;36(2):74-82. doi: 10.3109/07435800.2010.539993. Epub 2011 Mar 26. PMID: 21438725.
95. **Nuclear Export of FoxO1 Is Associated with ERK Signaling in β-Cells Lacking Insulin Receptors.** Mezza T, Shirakawa J, Martinez R, Hu J, Giaccari A, Kulkarni RN. J Biol Chem. 2016 Oct 7;291(41):21485-21495. doi: 10.1074/jbc.M116.735738. Epub 2016 Aug 17. PMID: 27535223; PMCID: PMC5076820.
96. **A. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?** Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, Della Casa S, Pontecorvi A, Giaccari Clin Nutr. 2012 Aug;31(4):476-80. doi: 10.1016/j.clnu.2011.12.010. Epub 2012 Jan 20. PMID: 22260937.
97. Postoperative hyperglycemia affects survival after gastrectomy for cancer: A single-center analysis using propensity score matching. **Fiorillo C, Quero G, Laterza V, Mascagni P, Longo F, Menghi R, Razionale F, Rosa F, Mezza T, Boskoski I, Giaccari A, Alfieri S.** Surgery. 2020 May;167(5):815-820. doi: 10.1016/j.surg.2019.11.006. Epub 2019 Dec 3. PMID: 31810521.
98. **High-normal TSH values in obesity: is it insulin resistance or adipose tissue's guilt?** Muscogiuri G, Sorice GP, Mezza T, Prioletta A, Lassandro AP, Pirronti T, Della Casa S,

Pontecorvi A, Giaccari A. Obesity (Silver Spring). 2013 Jan;21(1):101-6. doi: 10.1002/oby.20240. PMID: 23505173.

99. **Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.** Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer SA, Bonnemaire M, Sawhney S, Stewart J, Wang S, Castro RC, Garg SK. Diabetes Technol Ther. 2019 Sep;21(9):471-477. doi: 10.1089/dia.2019.0157. PMID: 31335194; PMCID: PMC6708262.
100. **IL-21 is a major negative regulator of IRF4-dependent lipolysis affecting Tregs in adipose tissue and systemic insulin sensitivity.** Fabrizi M, Marchetti V, Mavilio M, Marino A, Casagrande V, Cavalera M, Moreno-Navarrete JM, Mezza T, Sorice GP, Fiorentino L, Menghini R, Lauro R, Monteleone G, Giaccari A, Fernandez Real JM, Federici M. Diabetes. 2014 Jun;63(6):2086-96. doi: 10.2337/db13-0939. Epub 2014 Jan 15. PMID: 24430438.
101. **Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production.** Capece U, Pavanello C, Cinti F, Leccisotti L, Mezza T, Ciccarelli G, Moffa S, Di Giuseppe G, Soldovieri L, Brunetti M, Giordano A, Giaccari A, Calabresi L, Ossoli A. Diabetes Ther. 2024 Jan;15(1):257-268. doi: 10.1007/s13300-023-01491-5. Epub 2023 Oct 26. PMID: 37883003; PMCID: PMC10786750.
102. **Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.** Rodbard HW, Giaccari A, Lajara R, Stewart J, Strumph PS, Oliveira J, Lapuerta P, Castro R. Diabetes Obes Metab. 2020 Nov;22(11):2089-2096. doi: 10.1111/dom.14127. Epub 2020 Jul 28. PMID: 32618383.
103. **The size of adrenal incidentalomas correlates with insulin resistance.** Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi A, Della Casa S. Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Di Silvestre S, De Lutiis MA, Pellegrini G, Capani F, Consoli A, Felaco M.
104. **Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation.** J Cell Physiol. 2003 Aug;196(2):378-85. doi: 10.1002/jcp.10325. PMID: 12811832. Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Di Silvestre S, De Lutiis MA, Pellegrini G, Capani F, Consoli A, Felaco M. J Cell Physiol. 2003 Aug;196(2):378-85. doi: 10.1002/jcp.10325. PMID: 12811832.Is there a cause-effect relationship? Clin Endocrinol (Oxf). 2011 Mar;74(3):300-5. doi: 10.1111/j.1365-2265.2010.03928.x. PMID: 21070314.
105. **Società Italiana di Diabetologia-Associazione Medici Diabetologi (SID-AMD) Working Group on the Standards of Care for Diabetes. Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010"** Bruno G, De Micheli A, Frontoni S, Monge L. Nutr Metab Cardiovasc Dis. 2011 Apr;21(4):302-14. doi: 10.1016/j.numecd.2010.08.009. Epub 2010 Sep 18. PMID: 20851582.
106. **FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.** Iacobini C, Menini S, Blasetti Fantauzzi C, Pesce CM, Giaccari A, Salomone E, Lapolla A, Orioli M, Aldini G, Pugliese G. Br J Pharmacol. 2018 Jan;175(1):53-66. doi: 10.1111/bph.14070. Epub 2017 Dec 8. PMID: 29053168; PMCID: PMC5740255.
107. **Altered BAG3-insulin colocalization is associated with impaired first phase insulin secretion in humans.** Damiani V, Giuseppe GD, Gliozzo G, Ciccarelli G, Pizzinato E, Pizzo

FD, Fruci D, Brunetti M, Soldovieri L, Quero G, Mari A, Alfieri S, Pontecorvi A, Giaccari A, Laurenzi V, Mezza T. Diabetes Res Clin Pract. 2025 May 6:112232. doi: 10.1016/j.diabres.2025.112232. Epub ahead of print. PMID: 40339705.

108. **Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes.** Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E;Diabetes Care. 2007 Apr;30(4):932-8. doi: 10.2337/dc06-1696. PMID: 17392553.

109. **25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity.** Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Obesity (Silver Spring). 2010 Oct;18(10):1906-10. doi: 10.1038/oby.2010.11. Epub 2010 Feb 11. PMID: 20150902.

110. **Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.** Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. PMID: 31865758.

111. **Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study**. Bonadonna RC, Giaccari A, Buzzetti R, Perseghin G, Cucinotta D, Avogaro A, Aimaretti G, Larosa M, Fanelli CG, Bolli GB.Diabetes Metab Res Rev. 2020 Sep;36(6):e3304. doi: 10.1002/dmrr.3304. Epub 2020 Apr 5. PMID: 32118347; PMCID: PMC7540052.

112. **A single bout of physical exercise improves 1-hour post-load plasma glucose in healthy young adults** Moffa S, Sorice GP, Di Giuseppe G, Cinti F, Ciccarelli G, Soldovieri L, Brunetti M, Sonnino R, Nista EC, Gasbarrini A, Pontecorvi A, Mezza T, Giaccari A. J Endocrinol Invest. 2025 Feb;48(2):455-464. doi: 10.1007/s40618-024-02438-8. Epub 2024 Sep 30. PMID: 39347907; PMCID: PMC11785650.

113. **Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** Giaccari A, Giorda CB, Riccardi G, De Micheli A, Bruno G, Monge L, Frontoni S. Diabetes Care 2012;35:1364-1379. Diabetes Care. 2012 Oct;35(10):e71; author reply e72-3. doi: 10.2337/dc12-0784. PMID: 22996185; PMCID: PMC3447846.

114. **LIPIGEN Group. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.** Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S, Tarugi P, Catapano AL; Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002. PMID: 28965616.

115. **Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study.** Casula M, Olmastroni E, Pirillo A, Catapano AL; Atherosclerosis. 2018 Oct;277:413-418. doi: 10.1016/j.atherosclerosis.2018.08.013. PMID: 30270079.

116. **Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes: comment to Kayaniyil et al.** Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Diabetes Care. 2010

Jul;33(7):e99; author reply e100. doi: 10.2337/dc10-0587. PMID: 20587719.
117. **D-Carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation**. Menini S, Iacobini C, Ricci C, Scipioni A, Blasetti Fantauzzi C, Giaccari A, Salomone E, Canevotti R, Lapolla A, Orioli M, Aldini G, Pugliese G. Br J Pharmacol. 2012 Jun;166(4):1344-56. doi: 10.1111/j.1476-5381.2012.01834.x. PMID: 22229552; PMCID: PMC3417451.
118. **Self-monitoring of blood glucose: guideline application rather than utilization restrictions on testing strips has potential to reduce diabetes healthcare costs in Italy.** Giaccari A, Grassi G, Ozzello A. Diabetes Technol Ther. 2012 Oct;14(10):862-7. doi: 10.1089/dia.2012.0116. Epub 2012 Aug 6. PMID: 22866825.
119. **In humans increase in intrapancreatic adipose tissue predicts beta-cell dedifferentiation score before diabetes onset: A pilot study** Cinti F, Mezza T, Severi I, Moffa S, Giuseppe GD, Capece U, Ciccarelli G, Soldovieri L, Brunetti M, Morciano C, Gugliandolo S, Senzacqua M, Avolio A, Quero G, Tondolo V, Nista EC, Moroni R, Cinti S, Alfieri S, Gasbarrini A, Pontecorvi A, Giaccari A. I Diabetes Res. Clin. Pr. 221 (2025) MS N. 112029. doi: 10.1016/j.diabres.2025.112097. PMID: 40102093.
120. **High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7).** Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. Eur J Endocrinol. 2014 Dec;171(6):697-704. doi: 10.1530/EJE-14-0342. Epub 2014 Sep 11. PMID: 25213702.
121. **Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.** Bonora BM, Giaccari A, Consoli A, Broglio F, Avogaro A, Fadini GP; GLIMPLES Study Investigators. Diabetes Metab Res Rev. 2025 May;41(4):e70045. doi: 10.1002/dmrr.70045. PMID: 40277315; PMCID: PMC12023824.
122. **The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.** Petrone A, Suraci C, Capizzi M, Giaccari A, Bosi E, Tiberti C, Cossu E, Pozzilli P, Falorni A, Buzzetti R; NIRAD Study Group. Diabetes Care. 2008 Mar;31(3):534-8. doi: 10.2337/dc07-1457. Epub 2007 Dec 4. PMID: 18056891.
123. **Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation.** Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Di Silvestre S, De Lutiis MA, Pellegrini G, Capani F, Consoli A, Felaco M. J Cell Physiol. 2003 Aug;196(2):378-85. doi: 10.1002/jcp.10325. PMID: 12811832.
124. **Continuous subcutaneous insulin infusion (CSII) in inpatient setting: unmet needs and the proposal of a CSII unit.** Morviducci L, Di Flaviani A, Lauria A, Pitocco D, Pozzilli P, Suraci C, Frontoni S; CSII Study Group Of Lazio Region, Italy. Diabetes Technol Ther. 2011 Oct;13(10):1071-4. doi: 10.1089/dia.2011.0056. Epub 2011 Jun 29. PMID: 21714675.
125. **Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.** Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, Moschen AR, Muscogiuri G, Sorice GP, Kireva T, Summerer M, Wirtz S, Luther J, Mielenz D, Billmeier U, Egger G, Mayr A, Oberhollenzer F, Kronenberg F, Orthofer M, Penninger JM, Meigs JB, Bonora E, Tilg H, Willeit J, Schett G.Nat Med. 2013 Mar;19(3):358-63. doi: 10.1038/nm.3084. Epub 2013 Feb 10. PMID: 23396210.

126. **A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT.** Treglia G, Salomone E, Petrone G, Giaccari A, Rindi G, Rufini V. Clin Nucl Med. 2013 Jul;38(7):e306-8. doi: 10.1097/RLU.0b013e318279ec68. PMID: 23486330.
127. **GENFIEV Investigators. Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance.** Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S; Diabetes Care. 2012 Dec;35(12):2607-12. doi: 10.2337/dc11-2504. Epub 2012 Aug 21. PMID: 22912427; PMCID: PMC3507559.
128. **GENFIEV Investigators. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.** Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, Del Prato S; J Clin Endocrinol Metab. 2013 May;98(5):2100-5. doi: 10.1210/jc.2012-3971. Epub 2013 Mar 28. PMID: 23539736.
129. **Global Investigators. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.** Rissanen A, Howard CP, Botha J, Thuren T; Diabetes Obes Metab. 2012 Dec;14(12):1088-96. doi: 10.1111/j.1463-1326.2012.01637.x. Epub 2012 Jul 19. PMID: 22726220.